Cargando…

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application

INTRODUCTION: Patients with Alzheimer's disease (AD) are currently treated with cholinesterase inhibitors, such as galantamine, without actual knowledge of its concentration in plasma. Our objective was to analyse potential relationships between galantamine concentration, galantamine dose, soci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wattmo, Carina, Jedenius, Erik, Blennow, Kaj, Wallin, Åsa K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580330/ https://www.ncbi.nlm.nih.gov/pubmed/23286718 http://dx.doi.org/10.1186/alzrt156

Ejemplares similares

Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting
por: Wallin, Åsa K, et al.
Publicado: (2011)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years
por: Wattmo, Carina, et al.
Publicado: (2017)

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
por: Wattmo, Carina, et al.
Publicado: (2016)

Early-versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of Progression
por: Wattmo, Carina, et al.
Publicado: (2017)

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2020)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies
por: Wattmo, Carina, et al.
Publicado: (2013)

Predictors of long-term cognitive outcome in Alzheimer's disease
por: Wattmo, Carina, et al.
Publicado: (2011)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
por: Johansson, Per, et al.
Publicado: (2013)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention
por: Akilo, Olufemi D., et al.
Publicado: (2018)

The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease
por: Sasaki, Shoichi, et al.
Publicado: (2014)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
por: Gonzalez-Ortiz, Fernando, et al.
Publicado: (2023)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease
por: Hager, Klaus, et al.
Publicado: (2014)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
por: Adnan, Mohd, et al.
Publicado: (2023)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Short-Term Response to Cholinesterase Inhibitors in Alzheimer’s Disease Delays Time to Nursing Home Placement
por: Wattmo, Carina, et al.
Publicado: (2018)

Plasma neurofilament light chain concentration in the inherited peripheral neuropathies
por: Sandelius, Åsa, et al.
Publicado: (2018)

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano, Osamu, et al.
Publicado: (2013)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
por: Woo, Fong Yen, et al.
Publicado: (2015)

Solitary living in Alzheimer’s disease over 3 years: association between cognitive and functional impairment and community-based services
por: Wattmo, Carina, et al.
Publicado: (2014)

Plasma β-amyloid in Alzheimer’s disease and vascular disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Plasma biomarker profiles in autosomal dominant Alzheimer’s disease
por: Johansson, Charlotte, et al.
Publicado: (2023)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Hansen, Richard A, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_r5op95pil6sb5j0gcb2ae2co51